Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study

J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e416-e418. doi: 10.1111/jdv.16366. Epub 2020 May 8.
No abstract available

Publication types

  • Letter
  • Multicenter Study

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Biological Factors
  • Dermatologic Agents* / adverse effects
  • Humans
  • Psoriasis* / drug therapy
  • Retrospective Studies
  • Severity of Illness Index
  • Treatment Outcome
  • Ustekinumab / adverse effects

Substances

  • Antibodies, Monoclonal, Humanized
  • Biological Factors
  • Dermatologic Agents
  • ixekizumab
  • secukinumab
  • Ustekinumab